title: Fatty acid synthase (FAS): a target for cytotoxic antimetabolites in HL60 promyelocytic leukemia cells.
abstract: Many human cancers express elevated levels of fatty acid synthase (FAS), with correspondingly increased fatty acid synthesis and abnormal fatty acid utilization. Recent studies have shown that the FAS inhibitor, cerulenin, is selectively cytotoxic to cell lines derived from human malignancies, suggesting that those carcinoma cells are dependent upon endogenous fatty acid synthesis for growth. These data further suggest that the fatty acid synthesis pathway is a potential target for chemotherapy development. The present studies demonstrate that cerulenin cytotoxicity is mediated by fatty acid pathway inhibition. Proliferating HL60 promyelocytic leukemia cells express high levels of FAS mRNA and protein and synthesize fatty acid predominantly for membrane phospholipid. Following exposure to 12-O-tetradecanoylphorbol-13-acetate, the FAS expression in HL60 cells is abolished, fatty acid synthesis diminishes, and the cells become insensitive to cerulenin while acquiring a differentiated, macrophage-like phenotype. HL60 cells adapted to growth in serum- and fatty acid-free medium show a dose-dependent sensitivity to cerulenin, which is reversed by palmitate, the major product of FAS, indicating that cerulenin cytotoxicity is mediated through fatty acid starvation. Cells grown in the presence of exogenous fatty acid partially downmodulate FAS expression and increase mean cell volume (phospholipid mass/cell) but retain their sensitivity to cerulenin, which is reversed by 3-fold excess oleate supplementation. These results demonstrate that malignant cells can retain dependence on endogenous fatty acid synthesis and sensitivity to FAS inhibitors in the presence of physiological fatty acid levels and thus support the notion that FAS inhibitors may be useful in treating cancer in vivo.
authors.affiliation: Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA.
authors.forename: E S
authors.initials: ES
authors.lastname: Pizer
authors.forename: F D
authors.initials: FD
authors.lastname: Wood
authors.forename: G R
authors.initials: GR
authors.lastname: Pasternack
authors.forename: F P
authors.initials: FP
authors.lastname: Kuhajda
mesh_terms: D000970:Antineoplastic Agents / Q000633:toxicity*; D015152:Blotting, Northern; D002454:Cell Differentiation; D002569:Cerulenin / Q000633:toxicity*; D016895:Culture Media, Serum-Free; D064429:Fatty Acid Synthases / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D005230:Fatty Acids, Nonesterified / Q000494:pharmacology*; D005434:Flow Cytometry; D015870:Gene Expression / Q000187:drug effects; D018922:HL-60 Cells; D006801:Humans; D007700:Kinetics; D015473:Leukemia, Promyelocytic, Acute; D019301:Oleic Acid; D009829:Oleic Acids / Q000494:pharmacology; D019308:Palmitic Acid; D010169:Palmitic Acids / Q000494:pharmacology; D012333:RNA, Messenger / Q000096:biosynthesis; D012710:Serum Albumin, Bovine; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D016895:Culture Media, Serum-Free; D005230:Fatty Acids, Nonesterified; D009829:Oleic Acids; D010169:Palmitic Acids; D012333:RNA, Messenger; D002569:Cerulenin; D012710:Serum Albumin, Bovine; D019301:Oleic Acid; D019308:Palmitic Acid; D064429:Fatty Acid Synthases; D013755:Tetradecanoylphorbol Acetate